MAASTRO clinic
Maastricht, 6229 ET, Netherlands
NCT Number: NCT03564457
Machine learn a predictive model from more than 20.000 non-small cell lung cancer patients from more than 5 health care providers from more than 5 countries.
Looking for future studies?
Notify MeAll sexes
Observational
Maastricht, 6229 ET, Netherlands
All current innovations in medicine, including personalized medicine; artificial intelligence; (Big) data driven medicine; learning health care system; value based health care and decision support systems, rely on the sharing of data across health care providers. But sharing of data is hampered by administrative, political, ethical and technical barriers(Sullivan et al., 2011). This limits the amount of health data available for the above innovations and life sciences in general as well as other secondary uses such as quality improvement.
The investigators hypothesize that sharing questions rather than sharing data is a better approach and can unlock orders of magnitude more data while limiting privacy and other concerns. An infrastructure to bring questions to the data has been demonstrated to work recently in project such as euroCAT(Lambin et al., 2013; Deist et al., 2017), Datashield (Gaye et al., 2014) and OHDSI (Hripcsak et al., 2015). However, the scale of the prior work has been limited in terms of the number of data subjects, number of data providers and global coverage.
In the experience of the investigators, the main challenges of scaling up the infrastructure are 1) the effort necessary to make data FAIR at each site ("stations"), 2) the technical and legal governance ("track") and 3) the mathematics and engineering of learning applications ("trains") - together called the Personal Health Train (PHT) infrastructure. Since multiple years a global consortium of healthcare providers, scientists and commercial parties called CORAL (Community in Oncology for RApid Learning) have worked on all three PHT challenges.
The aim of this study is to show that the PHT distributed learning infrastructure can be scaled to many 1000s of patients, specifically the investigators aim to machine learn a predictive model from more than 20.000 non-small cell lung cancer patients from more than 5 health care providers from more than 5 countries.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No interventions will take place (observational)
Time frame: 2 years after (any) treatment for non small cell lung cancer
Overall survival
Maastricht Radiation Oncology
Other
Distributed Learning of a Survival Model in More Than 20.000 Lung Cancer Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05375994
Advanced Cancer, Bronchial Neoplasms
San Francisco, California, United States
View Trial DetailsNCT04939324
Bronchial Neoplasms, Carcinoma, Bronchogenic
Limoges, France
View Trial DetailsNCT00818558
Bronchial Neoplasms, Carcinoma, Bronchogenic
Nice, France
View Trial DetailsNCT06196424
Bronchial Neoplasms, Carcinoma, Bronchogenic
Milan, Italy
View Trial Details